Lightlake Therapeutics' intranasal naloxone prevents binge eating
13:20 EDT 10 Aug 2012 | SCRIP
The US early-stage biopharmaceutical company Lightlake Therapeutics hopes to provide a nasal spray version of naloxone for binge eating disorder based on positive Phase II results. The data from 127 Finnish patients suggest that the product,.....
Original Article: Lightlake Therapeutics' intranasal naloxone prevents binge eating
More From BioPortfolio on "Lightlake Therapeutics' intranasal naloxone prevents binge eating"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
